Kai Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kai Li has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Biao Liu
University of Chinese Academy of Sciences, Beijing, China
1 shared publicationBin Liang
University of Chinese Academy of Sciences, Beijing, China
1 shared publication- Changan Wang
University of Chinese Academy of Sciences, Beijing, China
1 shared publication - Chao Dong
Department of Medical Oncology, The First Affiliated Hospital of Kunming Medical University, Kunming, China
1 shared publication Deyu Kong
Department of Medical Oncology, The First Affiliated Hospital of Kunming Medical University, Kunming, China
1 shared publicationJiang Pan
School of Life Science and Technology, ShanghaiTech University, Shanghai, China
1 shared publication
Latest Publications
- Open Access
- 5 June 2026
- Published by Springer Nature in Cell Death & Disease
- Vol. 17 (1)
JOSD1-mediated stabilization of SUFU controls pancreatic cancer progression
The Hedgehog (Hh) signaling pathway plays an essential role in embryonic development, and its aberrant activation is associated with pancreatic cancer progression. However, the function of Suppressor of Fused (SUFU), a critical negative regulator of the Hh pathway, in pancreatic cancer has been poorly studied. In this study, we found that SUFU knockdown significantly inhibits pancreatic cancer cell growth, migration, and proliferation while inducing apoptosis. We identified a direct interaction between JOSD1 and SUFU, whereby JOSD1 stabilizes SUFU protein by inhibiting its ubiquitination and proteasomal degradation. Public database analyses revealed a positive correlation between JOSD1 and SUFU expression in pancreatic cancer tissues, and immunofluorescence staining of clinical samples further showed that JOSD1 and SUFU are co-localized and expressed at higher levels in pancreatic cancer tissues compared with normal pancreatic tissues. Notably, SUFU regulates pancreatic cancer cell behavior through a non-canonical, Hh-independent mechanism. Depletion of either JOSD1 or SUFU downregulated proliferation-related genes and upregulated apoptosis-related genes, thereby suppressing pancreatic cancer cell growth and promoting apoptosis, with these effects reversed by SUFU restoration. Consistently, silencing of JOSD1 or SUFU significantly attenuates tumor growth and reduces Ki67 expression in vivo, whereas re-expression of SUFU in JOSD1-deficient tumors restores tumor growth and proliferation. Collectively, these findings highlight the functional importance of JOSD1-mediated SUFU stabilization in pancreatic cancer and suggest potential therapeutic strategies targeting this axis.
- 5 June 2026
- Published by Springer Nature in Cell Death & Disease
- Vol. 17 (1)
Open AccessJOSD1-mediated stabilization of SUFU controls pancreatic cancer progression
The Hedgehog (Hh) signaling pathway plays an essential role in embryonic development, and its aberrant activation is associated with pancreatic cancer progression. However, the function of Suppressor of Fused (SUFU), a critical negative regulator of the Hh pathway, in pancreatic cancer has been poorly studied. In this study, we found that SUFU knockdown significantly inhibits pancreatic cancer cell growth, migration, and proliferation while inducing apoptosis. We identified a direct interaction between JOSD1 and SUFU, whereby JOSD1 stabilizes SUFU protein by inhibiting its ubiquitination and proteasomal degradation. Public database analyses revealed a positive correlation between JOSD1 and SUFU expression in pancreatic cancer tissues, and immunofluorescence staining of clinical samples further showed that JOSD1 and SUFU are co-localized and expressed at higher levels in pancreatic cancer tissues compared with normal pancreatic tissues. Notably, SUFU regulates pancreatic cancer cell behavior through a non-canonical, Hh-independent mechanism. Depletion of either JOSD1 or SUFU downregulated proliferation-related genes and upregulated apoptosis-related genes, thereby suppressing pancreatic cancer cell growth and promoting apoptosis, with these effects reversed by SUFU restoration. Consistently, silencing of JOSD1 or SUFU significantly attenuates tumor growth and reduces Ki67 expression in vivo, whereas re-expression of SUFU in JOSD1-deficient tumors restores tumor growth and proliferation. Collectively, these findings highlight the functional importance of JOSD1-mediated SUFU stabilization in pancreatic cancer and suggest potential therapeutic strategies targeting this axis.